Final Program [International Conference on AIDS (14th: 2002: Barcelona, Spain)]

Oral Sessions 14:oo - 15:30 Tuesday July 9

A05I Cellular Responses to HIV
Oral Abstract Session
Venue: Hall 1:1
Date: Tuesday, July o9, 2002
Time: 14:oo- 15:3o
Chairs: Clive Gray, South Africa
Douglas Nixon, United States
14:oo TuOrA1179 Acute cytotoxic T-lymphocyte escape is a
hallmark of simian immunodeficiency
virus infection
D H O'Connor, TM Allen, TU Vogel,
P Jing, I P DeSouza, EJ Dodds,
H Yamamoto, Ej Dunphy, B R Mothe,
A L Hughes, D I Watkins (United States)
14:15 TuOrA1182 Whole genome analysis of HIV-1 specific
cytotoxic T lymphocyte (CTL) responses
on single epitope level in different
groups of HIV-1 infected individuals
M Addo, X G Yu, A Rathod, D Cohen,
R Eldridge, M N Johnston, J T Blackard,
C Brander, S Boswell, PJ R Goulder,
ES Rosenberg, M Altfeld, B D Walker
(United States)
14:30 TuOrA1184 Cytotoxic T lymphocyte (CTL) responses
restricted by HLA-B7, -B42 and -B81 in
African HIV-1 positive women and their
babies
N Mnqqundaniso (South Africa)
14:45 TuOrA1181 Magnitude and frequency of CTL
responses to HIV-i subtype C
V Novitsky', N Rybak, MF McLane,
P Gilbert', S Gaolekwe2, TPeter, I Thior,
T Ndung'u', R Marlink, TH Lee1, M Essex'
(United States; 2Botswana)
15:oo TuOrA1183 Characterization of HIV-1 gag and env
specific responses in HIV-1 subtype Cinfected individuals in India
M R Thakar, S Keating2, L S Bhonge,
S Lakhashe', A K Rao1, R C Bollinger,
R S Paranjape (lndia; 2United States)
15:15 TuOrA118o HIV-specific cytotoxic T cell responses
persist in the lymphoid tissue during
HAART in chronic HIV infection and
redistribute after treatment interruption
J van Lunzen1, M Altfeld2, N Frahm2,
H JStellbrink, B D Walker2
(Germany; 2United States)
B07 Initial Therapy
Oral Abstract Session
Venue: Hall 2:1
Date: Tuesday, July 09, 2002
Time: 14:oo- 15:3o
Chairs: Brian Gazzard, United Kingdom
Daniel Podzamczer, Spain
14:oo TuOrB1185 Immunological and virological effects of
short course antiretroviral therapy in
primary HIV infection
S Fidler M D Brady, A Oxenius,
D Price, A Babiker, H T Zhang,
R Phillips, I N Weber (United Kingdom)
14:15 TuOrB1186 Comparison of two HAART sequences in
naive HIV-infected patients: a
randomized, multicenter, open label,
long term follow up clinical trial
i Mallolas g] L Blanco, ] M Pefa,

D Dalmau, A Ochoa, F Vidal, MA Ribas,
F Segura, E Pedrol, I Flores, A Cruceta, S
Varea, I Pich, E Martfnez, I M Gatell (Spain)

14:30 TuOrB1187
14:45 TuOrB1188
15:oo00 TuOrB1189
15:15 TuOrB157

Comparative study of efavirenz or
protease inhibitor-based HAART in HIVinfected, antiretroviral naive patients
with.....oo CD4 cel/μL and
opportunistic diseases (EFAVIP-2 study)
F Pulido, J R Arribas, J M Miro, A Costa,
R Rubio, J Gonzalez, J M Pena,
M Lonca, A Lorenzo, C Cepeda,
M Torralba, J M Gatell, EFAVIP Cohort
Study Group (Spain)
A randomised trial comparing HAART
regimens of Nelfinavir/Nevirapine (N/N)
and Ritonavir/Saquinavir (R/S) in PI and
NNRTI naive patients
0 Kirk, J D Lundgren, C Pedersen,
L Mathiesen, H Nielsen, T Katzenstein,
N Obel, J Gerstoft (Denmark)
Abacavir/Lamivudine (ABC/3TC) in
combination with Efavirenz (NNRTI),
Amprenavir/Ritonavir (PI) or Stavudine
(NRTI): ESS4000oool(CLASS) preliminary 48
week results
] A Bartlett, ] Johnson', G Herrera2,
N Sosa3, A E Rodriguez', M S Shaefer
(United States; 2Costa Rica; 3Panama)
Beginning antiretroviral therapy:
a world of options
Daniel Kuritzkes (United States)

Tuesday

NOTES

XIV International AIDS Conference BARCELONA - JULY 7-12

79